Zhaohui Su, VP of Biostatistics at Ontada, shared a post on LinkedIn:
“OncoDaily’s 2025 coverage reflects a transformative year in oncology, characterized by groundbreaking research, clinical innovation, and global collaboration. Major international congresses, including ASCO and ESMO, showcased practice-changing trials, biomarker-driven strategies, and significant advances in immunotherapy, targeted agents, and precision oncology.
Specialized meetings such as the San Antonio Breast Cancer Symposium, ESMO GI, CTOS, and SIOG provided valuable insights into breast and gastrointestinal cancers, rare tumors, and geriatric oncology, emphasizing the importance of individualized care and patient-centered decision-making.
Radiation oncology remained a focal point, with ASTRO and ESTRO highlighting adaptive technologies and integrated approaches. Cross-disciplinary forums addressed critical areas like cardio-oncology, policy, prevention, and integrative care, underscoring the growing significance of survivorship and holistic treatment strategies.
Educational initiatives, including the CUHK Masterclass and MASSC, reinforced global collaboration and knowledge exchange.
Overall, 2025 underscored resilience and innovation in cancer care, paving the way for continued progress in 2026.”
You can Read: OncoDaily 2025: A Year of Global Oncology Coverage and Scientific Progress
